Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Discussion of the AED workshop

D G Kasteleijn-Nolst Trenité1, J W Meijer

  • 1Instituut voor Epilepsiebestrijding, Heemstede, The Netherlands.

Pharmacy World & Science : PWS
|November 22, 1997
PubMed
Summary

Standardizing epilepsy drug reporting is crucial for patient safety and treatment effectiveness. Recommendations include comprehensive efficacy and side-effect data, teratogenicity information, and quality of life assessments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduction of exacerbation frequency in patients with COPD after participation in a comprehensive pulmonary rehabilitation program.

International journal of chronic obstructive pulmonary disease·2014
Same author

Image DNA-index (ploidy) analysis in cancer diagnosis.

Applied optics·2010
Same author

Whole-genome linkage scan for epilepsy-related photosensitivity: a mega-analysis.

Epilepsy research·2010
Same author

[Fibrosing mediastinitis: a rare cause of fever].

Nederlands tijdschrift voor geneeskunde·2004
Same author

Pokemon contagion.

Southern medical journal·2002
Same author

MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Journal of clinical pathology·2001

Area of Science:

  • Pharmacology and Neurology
  • Clinical Trial Design

Background:

  • Current epilepsy drug evaluation lacks standardized reporting for efficacy and adverse events.
  • Incomplete data on drug teratogenicity and patient-reported outcomes hinders comprehensive understanding.

Framework:

  • Propose standardized metrics for measuring seizure control, including complete remission and reduction in frequency/severity.
  • Advocate for detailed reporting of patient dropouts and their reasons in clinical trials.
  • Emphasize the need for robust data on teratogenicity through controlled trials or pregnancy registries for new anti-epileptic drugs.

Implementation:

  • Develop and validate reliable biomarkers for predicting drug efficacy and toxicity.
  • Incorporate health-related quality of life (HRQoL) scales, integrating subjective and objective patient feedback.
  • Encourage market introduction of drugs that enhance HRQoL, even if seizure suppression is moderately less effective.

Implications:

  • Improved clinical decision-making and patient care in epilepsy management.
  • Enhanced drug development and regulatory review processes for anti-epileptic medications.
  • Advancement of pharmaco-economic research to optimize resource allocation in epilepsy treatment.

Related Experiment Videos